达拉图穆马布治疗慢性炎症性脱叶林性多基基隆性神经病变 (CIDP):一个病例报告
Xueyu Zhang1, Jianli Zhao1, Xue Zhao2
1Department of Neurology, Tianjin Medical University General Hospital, Tianjin, China.
Annals of clinical and translational neurology
|November 27, 2025
概括
达拉图马布是一种抗CD38抗体,在治疗耐火性慢性炎症性脱叶林性多基基隆性神经病 (CIDP) 方面表现有前途. 本案例研究详细介绍了治疗耐药性CIDP患者的成功管理和一年的随访情况.
科学领域:
- 神经免疫学 神经免疫学
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性炎症性脱肌性多基基隆性神经病 (CIDP) 是一种免疫媒介疾病,导致渐进的虚弱和感官丧失.
- 标准治疗,如皮质类固醇,IVIg和血酶是有效的,但一小部分患者是不耐药的.
- 达拉图穆马布是一种抗CD38抗体,具有免疫调节作用,有可能导致神经免疫疾病.
研究的目的:
- 评估达拉图穆马布在患有治疗不耐药性CIDP的患者中的疗效.
- 提出对耐火性CIDP的达拉图穆马布治疗的长期随访数据.
主要方法:
- 一个患有耐火性CIDP的病人的病例报告.
- 用达拉图马布治疗,达拉图马布是一种抗CD38单克隆抗体.
- 临床评估和一年的随访.
主要成果:
- 耐火性CIDP患者在达拉图穆马布治疗后显著改善.
- 在一年的随访期间观察到持续的疗效和耐受性.
- 在这种耐治疗病例中,达拉图姆巴有效地控制了症状.
结论:
- 达拉图姆可能是耐火性CIDP患者的可行的治疗选择.
- 需要进一步的研究来确认daratumumab在较大的CIDP队列中的有效性和安全性.
- 这一案例凸显了向免疫疗法的潜力,用于管理耐药神经免疫疾病.
更多相关视频
相关概念视频
Drug Discovery: Overview
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Structure-Activity Relationships and Drug Design
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...

![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
